Hikma Pharmaceuticals PLC has agreed to a $50 million settlement in response to antitrust allegations concerning its narcolepsy medication, Xyrem. A certified class representing buyers from 36 states has requested a California federal judge’s preliminary approval of this deal. The claims center on accusations that Hikma conspired with Jazz Pharmaceuticals to obstruct generic versions from entering the market, thereby maintaining a competitive edge for Jazz’s product. Additional details can be found in the original article.